facebook pixel code
image of colored blocks


If you or a loved one has been diagnosed with Alzheimer’s disease, or your physician suspects it may be Alzheimer’s disease, you or they may be eligible to participate in one of two new clinical trials to help advance the treatment of Alzheimer’s disease.

Complete the Pre-Screener
RethinkALZ and RefocusALZ Clinical Research Studies

RethinkALZ and RefocusALZ Clinical Trials

RethinkALZ and RefocusALZ are the names of two new clinical trials for Alzheimer’s disease. The purpose of these trials is to determine if a new, twice-a-day, oral drug candidate called simufilam is safe and effective in slowing down the progression of mild-to-moderate Alzheimer’s disease. Simufilam is an investigational drug candidate that has not been approved by the US Food and Drug Administration (FDA), or any regulatory agency, for the treatment of any condition.

Clinical trials are research studies in which people volunteer to help find answers to specific health questions. When carefully conducted by doctors and nurses, clinical trials are the safest and fastest way to find new treatments and ways to improve health. For basic information about clinical trials, please visit: https://www.fda.gov/patients/clinical-trials-what-patients-need-know/basics-about-clinical-trials

To be considered for the RethinkALZ study or RefocusALZ trials, patients must:

  • Be ages 50 to 87 years old
  • Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease
  • Have a gradual change in memory for six months or more
  • Have a family member or loved one who can be available as a study partner during the entire study
  • Be fully vaccinated for COVID-19 or have had a previous COVID-19 infection

Other criteria apply.

Learn More About the Studies

Interested in participating?

See if you or your loved one would be eligible to participate in either the RethinkALZ or RefocusALZ clinical trials.

Complete the Pre-Screener

Refer A Friend

Do you know a family member or loved one who is diagnosed with Alzheimer’s disease? They may be eligible to participate in either the RethinkALZ or RefocusALZ clinical trials. Consider sharing information with them about how they can learn more.

Share this Study